$EXAS
EXACT SCIENCES CORP Stock $exas

$exas Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000112414021000029 Filed on February 16, 2021

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$295.6M	$218.8M	$199.9M
YoY Change	106.72%	84.97%	94.25%
Cost Of Revenue	$70.42M	$52.34M	$51.14M
YoY Change	86.15%	76.3%	92.59%
Gross Profit	$213.2M	$166.0M	$148.3M
YoY Change	102.73%	88.11%	95.13%
Gross Profit Margin	72.12%	75.89%	74.2%
Selling, General & Admin	$264.3M	$166.7M	$151.9M
YoY Change	98.64%	49.5%	61.68%
% of Gross Profit	123.96%	100.41%	102.43%
Research & Development	$43.22M	$34.71M	$29.97M
YoY Change	108.81%	99.51%	106.97%
% of Gross Profit	20.28%	20.91%	20.21%
Depreciation & Amortization	$26.00M	$8.400M	$7.100M
YoY Change	276.81%	37.7%	39.22%
% of Gross Profit	12.2%	5.06%	4.79%
Operating Expenses	$309.3M	$201.8M	$182.2M
YoY Change	101.16%	56.18%	67.61%
Operating Profit	-$96.11M	-$35.73M	-$33.90M
YoY Change	94.88%	-12.7%	3.67%
Interest Expense	-$10.60M	$13.21M	$12.71M
YoY Change	125.53%	23.4%	47.76%
% of Operating Profit
Other Income/Expense, Net	-$10.58M	-$4.116M	-$5.043M
YoY Change		-6.71%	36.81%
Pretax Income	-$106.7M	-$39.84M	-$38.95M
YoY Change	97.68%	-12.12%	7.03%
Income Tax	-$184.6M	$683.0K	-$443.0K
% Of Pretax Income
Net Earnings	$77.97M	-$40.53M	-$38.50M
YoY Change	-244.46%	-10.67%	5.81%
Net Earnings / Revenue	26.38%	-18.52%	-19.26%
Basic Earnings Per Share	$0.56	-$0.31	-$0.30
Diluted Earnings Per Share	$0.54	-$0.31	-$0.30
COMMON SHARES
Basic Shares Outstanding	139.9M shares	129.6M shares	129.2M shares
Diluted Shares Outstanding	143.2M shares	129.6M shares	129.2M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$323.7M	$1.161B	$1.239B
YoY Change	-71.21%	-2.08%	1.41%
Cash & Equivalents	$177.3M	$1.034B	$205.1M
Short-Term Investments	$146.4M	$126.2M	$1.034B
Other Short-Term Assets	$38.20M	$23.60M	$23.70M
YoY Change	86.34%	-0.84%	43.64%
Inventory	$61.72M	$53.67M	$47.78M
Prepaid Expenses
Receivables	$130.4M	$82.20M	$63.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$553.9M	$1.320B	$1.375B
YoY Change	-54.89%	2.36%	4.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$455.3M	$370.5M	$335.5M
YoY Change	85.65%	96.57%	138.79%
Goodwill	$1.203B	$17.28M	$17.28M
YoY Change	6863.35%
Intangibles	$1.144B
YoY Change	3843.0%
Long-Term Investments
YoY Change
Other Assets	$23.32M	$24.37M	$26.60M
YoY Change	428.11%	170.81%	202.3%
Total Long-Term Assets	$2.952B	$439.3M	$407.1M
YoY Change	897.39%	99.68%	136.16%
TOTAL ASSETS
Total Short-Term Assets	$553.9M	$1.320B	$1.375B
Total Long-Term Assets	$2.952B	$439.3M	$407.1M
Total Assets	$3.506B	$1.759B	$1.782B
YoY Change	130.03%	16.54%	20.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.97M	$19.16M	$19.90M
YoY Change	-7.7%	-41.41%	80.87%
Accrued Expenses	$193.3M	$134.8M	$151.0M
YoY Change	92.09%	90.44%	135.22%
Deferred Revenue	$600.0K	$700.0K	$700.0K
YoY Change	20.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$834.0K	$316.2M	$312.0M
YoY Change	10325.0%		6682.61%
Total Short-Term Liabilities	$236.5M	$480.7M	$492.5M
YoY Change	73.68%	350.51%	493.33%
LONG-TERM LIABILITIES
Long-Term Debt	$24.03M	$500.8M	$494.0M
YoY Change	-1.89%	-25.63%	-23.86%
Other Long-Term Liabilities	$34.91M	$29.51M	$29.92M
YoY Change	97.58%	132.37%	360.37%
Total Long-Term Liabilities	$58.94M	$29.51M	$29.92M
YoY Change	39.8%	-95.7%	-95.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$236.5M	$480.7M	$492.5M
Total Long-Term Liabilities	$58.94M	$29.51M	$29.92M
Total Liabilities	$1.218B	$1.011B	$1.016B
YoY Change	44.44%	27.52%	37.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.120B	-$1.198B	-$1.157B
YoY Change	8.11%
Common Stock	$3.408B	$1.946B	$1.921B
YoY Change	98.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.958B	$748.3M	$765.5M
YoY Change
Total Liabilities & Shareholders Equity	$3.506B	$1.759B	$1.782B
YoY Change	130.03%	16.54%	20.18%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$77.97M	-$40.53M	-$38.50M
YoY Change	-244.46%	-10.67%	5.81%
Depreciation, Depletion And Amortization	$26.00M	$8.400M	$7.100M
YoY Change	276.81%	37.7%	39.22%
Cash From Operating Activities	-$25.40M	-$29.10M	$17.00M
YoY Change	3075.0%	609.76%	-166.67%
INVESTING ACTIVITIES
Capital Expenditures	-$41.20M	-$51.70M	-$69.00M
YoY Change	-21.67%	-3.54%	137.11%
Acquisitions
YoY Change
Other Investing Activities	-$797.0M	$909.1M	-$33.50M
YoY Change	-1962.15%	-3679.13%	-67.06%
Cash From Investing Activities	-$838.1M	$857.4M	-$102.5M
YoY Change	8452.04%	-1185.32%	-21.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.600M	1.000M	5.500M
YoY Change	-29.03%	-94.76%	-97.64%
NET CHANGE
Cash From Operating Activities	-25.40M	-29.10M	17.00M
Cash From Investing Activities	-838.1M	857.4M	-102.5M
Cash From Financing Activities	6.600M	1.000M	5.500M
Net Change In Cash	-856.9M	829.3M	-80.00M
YoY Change	65815.38%	-1395.78%	-203.9%
FREE CASH FLOW
Cash From Operating Activities	-$25.40M	-$29.10M	$17.00M
Capital Expenditures	-$41.20M	-$51.70M	-$69.00M
Free Cash Flow	$15.80M	$22.60M	$86.00M
YoY Change	-69.5%	-54.34%	2288.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001124140
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-35092
CY2020	dei	Entity Registrant Name EntityRegistrantName	EXACT SCIENCES CORPORATION
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	5505 Endeavor Lane
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Madison
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	WI
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0478229
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	53719
CY2020	dei	City Area Code CityAreaCode	608
CY2020	dei	Local Phone Number LocalPhoneNumber	284‑5700
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.01 Par Value
CY2020	dei	Trading Symbol TradingSymbol	EXAS
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	12901152054	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	169093162	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1491288000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177254000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	348699000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	146401000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	233185000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130362000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	92265000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38195000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	61724000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33157000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2198594000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	553936000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	450683000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	455325000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125947000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126444000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1237672000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1203197000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	848426000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1143550000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	63770000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23316000	USD
CY2020Q4	us-gaap	Assets Assets	4925092000	USD
CY2019Q4	us-gaap	Assets Assets	3505768000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	35709000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	25973000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	233604000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193329000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11483000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7891000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	255464000	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1319000	USD
CY2019Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	834000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	38265000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8467000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	575844000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	236494000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1320760000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	803605000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	22342000	USD
CY2019Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	24032000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61582000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34911000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121075000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	118665000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2101603000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1217707000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	159423410	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	159423410	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	147625696	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147625696	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1595000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1477000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4789657000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3406440000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	526000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1968289000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1119756000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2823489000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2288061000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4925092000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3505768000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1491391000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	876293000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	454462000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	354324000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	216717000	USD
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	116644000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	554052000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	139694000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67285000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	589919000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	385176000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	249448000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	481716000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	352453000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	178016000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93398000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16035000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2540000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	209666000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	2283075000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1110075000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	613933000	USD
CY2020	us-gaap	Other Operating Income OtherOperatingIncome	23665000	USD
CY2019	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
CY2018	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-768019000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-233782000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-159471000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	6897000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	26530000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	21203000	USD
CY2020	us-gaap	Interest Expense InterestExpense	95983000	USD
CY2019	us-gaap	Interest Expense InterestExpense	61599000	USD
CY2018	us-gaap	Interest Expense InterestExpense	36789000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-89086000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35069000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15586000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-857105000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-268851000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-175057000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8572000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-184858000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-848533000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-83993000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-175149000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.61
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	151137000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	131257000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122207000	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-848533000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-83993000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-175149000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	771000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1322000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-708000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	25000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	36000	USD
CY2020	exas	Comprehensive Income Loss Before Tax Attributable To Parent ComprehensiveIncomeLossBeforeTaxAttributableToParent	-847737000	USD
CY2019	exas	Comprehensive Income Loss Before Tax Attributable To Parent ComprehensiveIncomeLossBeforeTaxAttributableToParent	-82671000	USD
CY2018	exas	Comprehensive Income Loss Before Tax Attributable To Parent ComprehensiveIncomeLossBeforeTaxAttributableToParent	-175821000	USD
CY2020	exas	Comprehensive Income Loss Tax Attributable To Parent ComprehensiveIncomeLossTaxAttributableToParent	170000	USD
CY2019	exas	Comprehensive Income Loss Tax Attributable To Parent ComprehensiveIncomeLossTaxAttributableToParent	0	USD
CY2018	exas	Comprehensive Income Loss Tax Attributable To Parent ComprehensiveIncomeLossTaxAttributableToParent	0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-847907000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82671000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175821000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	520418000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	260246000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6636000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	4303000	USD
CY2018	exas	Compensation Expense Related To Issuance Of Stock Options And Restricted Stock Awards Values CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues	60264000	USD
CY2018	exas	Purchase Of Employee Stock Purchase Plan Values PurchaseOfEmployeeStockPurchasePlanValues	4895000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-175149000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-672000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	680941000	USD
CY2019	exas	Debt Instrument Convertible Equity Component Consideration Settled DebtInstrumentConvertibleEquityComponentConsiderationSettled	300768000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	182477000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	268368000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8787000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	7409000	USD
CY2019	exas	Compensation Expense Related To Issuance Of Stock Options And Restricted Stock Awards Values CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues	108483000	USD
CY2019	exas	Purchase Of Employee Stock Purchase Plan Values PurchaseOfEmployeeStockPurchasePlanValues	8396000	USD
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1407080000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	441000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-83993000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1322000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2288061000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	346641000	USD
CY2020	exas	Debt Instrument Convertible Equity Component Consideration Settled DebtInstrumentConvertibleEquityComponentConsiderationSettled	64199000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27077000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	12007000	USD
CY2020	exas	Compensation Expense Related To Issuance Of Stock Options And Restricted Stock Awards Values CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues	152906000	USD
CY2020	exas	Purchase Of Employee Stock Purchase Plan Values PurchaseOfEmployeeStockPurchasePlanValues	18355000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	28847000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	861701000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-848533000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	626000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2823489000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-848533000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-83993000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-175149000	USD
CY2020	exas	Depreciation And Amortization Of Fixed Assets DepreciationAndAmortizationOfFixedAssets	69964000	USD
CY2019	exas	Depreciation And Amortization Of Fixed Assets DepreciationAndAmortizationOfFixedAssets	34212000	USD
CY2018	exas	Depreciation And Amortization Of Fixed Assets DepreciationAndAmortizationOfFixedAssets	20544000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2470000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1394000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-353000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1179000	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-207000	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	60264000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-765000	USD
CY2020	exas	Deferred Income Tax Expense Benefit Related To Acquisitions DeferredIncomeTaxExpenseBenefitRelatedToAcquisitions	-9862000	USD
CY2019	exas	Deferred Income Tax Expense Benefit Related To Acquisitions DeferredIncomeTaxExpenseBenefitRelatedToAcquisitions	-185109000	USD
CY2018	exas	Deferred Income Tax Expense Benefit Related To Acquisitions DeferredIncomeTaxExpenseBenefitRelatedToAcquisitions	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	152906000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	108483000	USD
CY2020	exas	Loss On Settlement Of Convertible Notes LossOnSettlementOfConvertibleNotes	7954000	USD
CY2019	exas	Loss On Settlement Of Convertible Notes LossOnSettlementOfConvertibleNotes	10558000	USD
CY2018	exas	Loss On Settlement Of Convertible Notes LossOnSettlementOfConvertibleNotes	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	76479000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	42256000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28564000	USD
CY2020	exas	Amortization Of Liabilities AmortizationOfLiabilities	3889000	USD
CY2019	exas	Amortization Of Liabilities AmortizationOfLiabilities	4467000	USD
CY2018	exas	Amortization Of Liabilities AmortizationOfLiabilities	2394000	USD
CY2020	exas	Increase Decrease In Amortization Of Premium On Short Term Investments IncreaseDecreaseInAmortizationOfPremiumOnShortTermInvestments	1549000	USD
CY2019	exas	Increase Decrease In Amortization Of Premium On Short Term Investments IncreaseDecreaseInAmortizationOfPremiumOnShortTermInvestments	-3102000	USD
CY2018	exas	Increase Decrease In Amortization Of Premium On Short Term Investments IncreaseDecreaseInAmortizationOfPremiumOnShortTermInvestments	-3516000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93398000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16035000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2540000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	412568000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	209666000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	15720000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	5427000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19041000	USD
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	100526000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27633000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17292000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30310000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12729000	USD
CY2020	exas	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8784000	USD
CY2019	exas	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4114000	USD
CY2018	exas	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	55165000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3469000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33076000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-41726000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	6237000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	3966000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	136482000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111655000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68940000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1089953000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	634117000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1192506000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	886675000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1657204000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	578786000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64352000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	171802000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	150093000	USD
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	15947000	USD
CY2019	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1000000	USD
CY2018	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6658000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	973861000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	17908000	USD
CY2020	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	411421000	USD
CY2019	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0	USD
CY2018	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	381000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	852000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	578000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-702037000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124428000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-782299000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1125547000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	729477000	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	896430000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	4895000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	8396000	USD
CY2020	exas	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P1Y
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	27077000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8787000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6636000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	861701000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	18355000	USD
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	150054000	USD
CY2019	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	493356000	USD
CY2018	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	319000	USD
CY2018	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	24236000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-3005000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-442000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2685000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	10265000	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	33452000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	2092000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	771000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	1322000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-708000	USD
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	136559	shares
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2019	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	86532	shares
CY2018	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	86882	shares
CY2020	exas	Issuance Of Stock To Fund Matching Contributions IssuanceOfStockToFundMatchingContributions	12007000	USD
CY2019	exas	Issuance Of Stock To Fund Matching Contributions IssuanceOfStockToFundMatchingContributions	7409000	USD
CY2018	exas	Issuance Of Stock To Fund Matching Contributions IssuanceOfStockToFundMatchingContributions	4303000	USD
CY2019	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2159716	shares
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1407080000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	182477000	USD
CY2018	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	exas	Debt Instrument Convertible Equity Component Consideration Settled DebtInstrumentConvertibleEquityComponentConsiderationSettled	64199000	USD
CY2019	exas	Debt Instrument Convertible Equity Component Consideration Settled DebtInstrumentConvertibleEquityComponentConsiderationSettled	300768000	USD
CY2018	exas	Debt Instrument Convertible Equity Component Consideration Settled DebtInstrumentConvertibleEquityComponentConsiderationSettled	0	USD
CY2020	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	386293	shares
CY2019	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	17046159	shares
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	28847000	USD
CY2020	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2019	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2018	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	3060000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9384000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5128000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	4638000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of convertible notes, valuation of intangible assets and goodwill, and accounting for income taxes among others.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the cancer screening and diagnostics industry. The COVID-19 outbreak, which the World Health Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to enact broad precautionary measures, including “stay-at-home” orders, restrictions on the performance of “non-essential” services, public gatherings and travel. Health systems, including key markets where the Company operates, have been, or may be, overwhelmed with high volumes of patients suffering from COVID-19. Even in areas where “stay-at-home” restrictions have been lifted and the number of cases of COVID-19 has declined, many individuals remain cautious about resuming activities such as preventive-care medical visits. Medical practices continue to be cautious about allowing individuals, such as sales representatives, into their offices. Many individuals continue to work from home rather from an office setting. The Company cannot forecast when the COVID-19 pandemic will end or the extent to which practices that have emerged during the pandemic will continue once it subsides.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2020 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, equity investments, software, and the carrying value of the goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic and related precautionary measures began to materially disrupt the Company's operations in March 2020 and may continue to disrupt the business for an unknown period of time. As a result, the pandemic had a significant impact on the Company's 2020 revenues and operating results.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received $23.7 million from the United States Department of Health and Human Services (“HHS”) as a distribution from the Public Health and Social Services Emergency Fund provided for in the CARES Act. The fund payments are grants, not loans, and HHS will not require repayment provided the funds are utilized to offset expenses incurred to address COVID-19 or to replace lost revenues. The Company accepted the terms and conditions of the grant in May 2020 and recognized the entire $23.7 million during the year ended December 31, 2020, due to lost revenue attributable to COVID-19, which is reflected in other operating income in the consolidated statement of operations. The Company cannot predict the extent to which it might receive any additional funds to be paid out under the Provider Relief Fund, and to what extent the financial impact of receiving such funds might offset the broad implications of the COVID-19 pandemic, which include increases in the Company’s costs and lost revenues.</span></div>
CY2020Q2	exas	Cares Act Grant Payment Received CARESActGrantPaymentReceived	23700000	USD
CY2020	exas	Cares Act Grant Payment Received CARESActGrantPaymentReceived	23700000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27284000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19280000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20822000	shares
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	554100000	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	237000000.0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $237.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2020, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype DX, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Revenue for the years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Accounts Receivable at December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Payer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State of Wisconsin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td></tr></table></div>
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1314066000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	139700000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67300000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	412600000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	93200000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	88700000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	93700000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1945000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1879621000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	253181000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	934142000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17098000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82939000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177528000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160430000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77491000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1491594000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177528000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160430000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36900000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-89200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	157600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120700000	USD
CY2020	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2020 and 2019.</span></div>
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation in the consolidated financial statements and accompanying notes to the consolidated financial statements.</span></div>
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1491391000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	876293000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	454462000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25000000.0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	600000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1491594000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	177528000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1521000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1716000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	348699000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	146401000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1840293000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	323929000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	936476000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	696000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	937172000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	175082000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	87000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	175007000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	890811000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	891110000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	45665000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	46062000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	144685000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	87000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	144685000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	103000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	87000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	100000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	3400000	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	400000	USD
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	200000	USD
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	200000	USD
CY2018	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	43083000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	24958000	USD
CY2020Q4	exas	Inventory Finished Semi Finished Goods InventoryFinishedSemiFinishedGoods	49182000	USD
CY2019Q4	exas	Inventory Finished Semi Finished Goods InventoryFinishedSemiFinishedGoods	36766000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	92265000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	61724000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	587300000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	532956000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	136617000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	77631000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	450683000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	455325000	USD
CY2020	us-gaap	Depreciation Depreciation	69400000	USD
CY2019	us-gaap	Depreciation Depreciation	33900000	USD
CY2018	us-gaap	Depreciation Depreciation	20500000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	960133000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	111810000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	848323000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	103000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	960236000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	111810000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	848426000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	963690000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	20411000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	943279000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1163961000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	20411000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1143550000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	93401000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	93196000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	92876000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	92422000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	233604000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	91374000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	385054000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	848323000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q4	us-gaap	Goodwill Goodwill	17279000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1185918000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1203197000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	30431000	USD
CY2020	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	4044000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1237672000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2879000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	325000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	77000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2477000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	117273000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	95166000	USD
CY2020Q4	exas	Promotional Agreement Accrued Expenses PromotionalAgreementAccruedExpenses	46937000	USD
CY2019Q4	exas	Promotional Agreement Accrued Expenses PromotionalAgreementAccruedExpenses	33230000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	36113000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	29108000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20735000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13976000	USD
CY2020Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	2118000	USD
CY2019Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	10720000	USD
CY2020Q4	exas	Accrued Research And Trial Related Expenses Current AccruedResearchAndTrialRelatedExpensesCurrent	5911000	USD
CY2019Q4	exas	Accrued Research And Trial Related Expenses Current AccruedResearchAndTrialRelatedExpensesCurrent	8368000	USD
CY2020Q4	exas	Accrued Licenses Current AccruedLicensesCurrent	4517000	USD
CY2019Q4	exas	Accrued Licenses Current AccruedLicensesCurrent	2761000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193329000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1319000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	22431000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	23750000	USD
CY2020	us-gaap	Regulatory Liability Amortization Period RegulatoryLiabilityAmortizationPeriod	P2Y
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8000000.0	USD
CY2020	exas	Debt Instrument Repurchase Price Due To Change In Control As Percentage Of Principal Amount DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount	100
	exas	Number Of Notes Converted During Period NumberOfNotesConvertedDuringPeriod	55	note
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	132.49
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4207000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2661000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2273000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	72272000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	39595000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	26291000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7954000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10558000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	exas	Coupon Interest Expense CouponInterestExpense	9631000	USD
CY2019	exas	Coupon Interest Expense CouponInterestExpense	7325000	USD
CY2018	exas	Coupon Interest Expense CouponInterestExpense	7823000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	94064000	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	60139000	USD
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	36387000	USD
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	1919000	USD
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	1460000	USD
CY2018	us-gaap	Interest Expense Other InterestExpenseOther	402000	USD
CY2020	us-gaap	Interest Expense InterestExpense	95983000	USD
CY2019	us-gaap	Interest Expense InterestExpense	61599000	USD
CY2018	us-gaap	Interest Expense InterestExpense	36789000	USD
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2019Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	17000000.0	shares
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	400000	USD
CY2020Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	400000	shares
CY2020Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8600000	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	101.00
CY2020Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	861700000	USD
CY2020Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7500000	USD
CY2018	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-989000	USD
CY2018	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-317000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-672000	USD
CY2019	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	681000	USD
CY2019	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-641000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1322000	USD
CY2020	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	771000	USD
CY2020	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-25000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	796000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	170000	USD
CY2020	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-25000	USD
CY2019	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-641000	USD
CY2018	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-317000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27100000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	152906000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108483000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60264000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	262500000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M17D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	3900000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2700293	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.01
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	309143	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	97.66
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	707013	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	39.07
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71364	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	82.76
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2231059	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	207090000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2231059	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	39.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	207090000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1399721	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.53
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	153912000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	40600000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	52000000.0	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	53000000.0	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8800000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6600000	USD
CY2020	exas	Number Of Employees Performance Based Equity Awards Impacted By Change In Operational Milestones NumberOfEmployeesPerformanceBasedEquityAwardsImpactedByChangeInOperationalMilestones	36	employees
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1935000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000	USD
CY2020	exas	Share Based Compensation Arrangement By Share Based Payment Award Performance Share Units Percentage Earned Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceShareUnitsPercentageEarnedMinimum	0
CY2020	exas	Share Based Compensation Arrangement By Share Based Payment Award Performance Share Units Percentage Earned Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceShareUnitsPercentageEarnedMaximum	2
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	12657752	shares
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2703000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	896000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	383000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	22551000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	9200000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	356000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	219000	USD
CY2020	us-gaap	Lease Cost LeaseCost	27928000	USD
CY2019	us-gaap	Lease Cost LeaseCost	10344000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	17531000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	9641000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	381000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1756000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13261000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	51030000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	20349000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	237000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M4D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0680
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0680
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0567
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0560
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125900000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126400000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	132600000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11500000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121100000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	126600000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7900000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	118700000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	20600000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	300000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	18700000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4700000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000000.0	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	200000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	32000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19881000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19596000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	21306000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	21257000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	19338000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	79141000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	180519000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	47961000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	132558000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	5674000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	5635000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	5525000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3819000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	53000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	20706000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1961000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	18745000	USD
CY2020Q4	exas	Lessee Operating Lease Lease Not Yet Commenced Asset LesseeOperatingLeaseLeaseNotYetCommencedAsset	8200000	USD
CY2020Q4	exas	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	8300000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3600000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	22800000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	12500000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	7400000	USD
CY2020Q1	us-gaap	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1	8400000	USD
CY2020Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	90	country
CY2019Q4	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	2470000000	USD
CY2020Q4	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	416500000	USD
CY2020	exas	Asset Acquisition Transaction Costs Incurred AssetAcquisitionTransactionCostsIncurred	4600000	USD
CY2020Q4	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	416525000	USD
CY2020Q4	exas	Asset Acquisition Transaction Costs Incurred AssetAcquisitionTransactionCostsIncurred	4600000	USD
CY2020Q4	exas	Asset Acquisition Payments To Acquire Productive Asset Net AssetAcquisitionPaymentsToAcquireProductiveAssetNet	421125000	USD
CY2020Q4	exas	Asset Acquisition Assets Acquired And Liabilities Assumed Cash AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedCash	9704000	USD
CY2020Q4	exas	Asset Acquisition Assets Acquired And Liabilities Assumed In Process Research And Development AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment	412568000	USD
CY2020Q4	exas	Asset Acquisition Assets Acquired And Liabilities Assumed Other Assets Liabilities AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilities	-1147000	USD
CY2020Q4	exas	Asset Acquisition Assets Acquired And Liabilities Assumed Net AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet	421125000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1491391000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	876293000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	454462000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	218000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-857105000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-268851000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-451067000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-267832000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-175275000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-406038000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1019000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-175057000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8572000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-184858000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	369642000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	369695000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	64760000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	51030000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	48349000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	33378000	USD
CY2020Q4	exas	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	31938000	USD
CY2019Q4	exas	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	30782000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6136000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7049000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	520825000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	491934000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	157629000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120679000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4078000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	363196000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	371255000	USD
CY2020Q4	exas	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	145925000	USD
CY2019Q4	exas	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	83163000	USD
CY2020Q4	exas	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	197847000	USD
CY2019Q4	exas	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	270421000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4580000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5913000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	30312000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	29586000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2607000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	382742000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	391690000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	19546000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	20435000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	157600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120700000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	19500000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36900000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-89200000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.091
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.016
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.011
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.019
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.221
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.091
CY2020	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostPercent	-0.008
CY2019	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostPercent	-0.041
CY2018	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostPercent	-0.049
CY2020	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	-0.001
CY2019	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	-0.007
CY2018	exas	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.127
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.240
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.317
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.009
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.688
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.009
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.009
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.688
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.688
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	16600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	10300000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1900000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10276000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1926000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3600000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2142000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	392000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2753000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	6208000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1534000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16629000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10276000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1926000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	347821000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	268868000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	408363000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	466339000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	81606000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	77892000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	95061000	USD
CY2020Q4	us-gaap	Cost Of Revenue CostOfRevenue	99765000	USD
CY2020Q1	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	20464000	USD
CY2020Q2	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	20555000	USD
CY2020Q3	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	20555000	USD
CY2020Q4	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	20553000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	245751000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	170421000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	292747000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	346021000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	328124000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	237430000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	496082000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	761323000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25056000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20000000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21059000	USD
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22971000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1732000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-867000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4510000	USD
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1463000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-105697000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-86142000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-40525000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	77973000	USD
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.79
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148151000	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-219884000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-436810000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.79
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	149727000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150155000	shares
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156470000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148151000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149727000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150155000	shares
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156470000	shares
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	162043000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	199870000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	218805000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	295575000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	42827000	USD
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	51139000	USD
CY2019Q3	us-gaap	Cost Of Revenue CostOfRevenue	52335000	USD
CY2019Q4	us-gaap	Cost Of Revenue CostOfRevenue	70416000	USD
CY2019Q1	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	425000	USD
CY2019Q2	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	424000	USD
CY2019Q3	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	424000	USD
CY2019Q4	exas	Amortization Of Intangible Assets Including Purchase Accounting Transactions AmortizationOfIntangibleAssetsIncludingPurchaseAccountingTransactions	11981000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	118791000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	148307000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4116000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	166046000	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	213178000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	186865000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	182209000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	201772000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	309258000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15335000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5043000	USD
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10575000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-470000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-443000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	683000	USD
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-184628000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-82939000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38502000	USD
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126248000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129182000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129567000	shares
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139901000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126248000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129182000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129567000	shares
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143200000	shares

Files In Submission

Name	View Source	Status
0001124140-21-000029-index-headers.html	Edgar Link	pending
0001124140-21-000029-index.html	Edgar Link	pending
0001124140-21-000029.txt	Edgar Link	pending
0001124140-21-000029-xbrl.zip	Edgar Link	pending
exas-20201231.htm	Edgar Link	pending
exas-20201231.xsd	Edgar Link	pending
exas-20201231xex1025.htm	Edgar Link	pending
exas-20201231xex231.htm	Edgar Link	pending
exas-20201231xex46.htm	Edgar Link	pending
exas-20201231xexx1016.htm	Edgar Link	pending
exas-20201231xexx1017.htm	Edgar Link	pending
exas-20201231xexx21.htm	Edgar Link	pending
exas-20201231xexx232.htm	Edgar Link	pending
exas-20201231xexx311.htm	Edgar Link	pending
exas-20201231xexx312.htm	Edgar Link	pending
exas-20201231xexx32.htm	Edgar Link	pending
exas-20201231_cal.xml	Edgar Link	unprocessable
exas-20201231_def.xml	Edgar Link	unprocessable
exas-20201231_htm.xml	Edgar Link	completed
exas-20201231_lab.xml	Edgar Link	unprocessable
exas-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXAS
EXACT SCIENCES CORP Stock $exas

2019 Q4 Form 10-K Financial Statement

#000112414021000029 Filed on February 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXAS EXACT SCIENCES CORP Stock $exas

2019 Q4 Form 10-K Financial Statement

#000112414021000029 Filed on February 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXAS
EXACT SCIENCES CORP Stock $exas